iwCLL

1-888-476-9129 info@bioascend.com

Menu
Saturday, May 13

Did you miss this year’s iwCLL 2017? Presentations available regarding state-of the-art concepts emerging from clinic-based and laboratory-based research about the pathobiology and treatment of CLL. This information is organized around the development, progression, and evolution of CLL.

To view the presentations from this iwCLL 2017, please click on individual presentations below. To access each day, please select the individual tabs organized by the workshop days.

 

Welcome and Introductions 

Opening remarks
Nicholas Chiorazzi
Reminiscences of meetings past
Kanti Rai and Jacques-Louis Binet
view_pres-01

  

I. UNRAVELING THE FACTORS LEADING TO THE DEVELOPMENT OF CLL

Session 1A         Inherited and Acquired Genetic Factors Involved in the Development of CLL
Chairs 1A: Daniel Catovsky and Stephan Stilgenbauer

Monoclonal B-Lymphocytosis:
Recent Clinical and Biologic Insights
Tait Shanafelt
Presentation
Not Available
Insights Into Inherited Susceptibility to
Chronic Lymphocytic Leukemia
Richard Houlston
view_pres-01
What is the Cell of Origin of CLL?
Olivier A. Bernard
view_pres-01
Chairs: Emili Monsterrat and John Gribben
Functional Evaluation of Key Recurrent Somatic
Mutations in CLL
Catherine Wu
Presentation
Not Available
Influences of Regulatory RNAs on CLL Development
Carlo M. Croce
 view_pres-01
New Insights Revealed by Epigenetic Studies in CLL
Christopher Oakes
 view_pres-01
*Mutations in NOTCH1 PEST Domain Confers Growth
Advantage to CLL Cells
Francesca Arruga
Presentation
Not Available

 

Session 2         Role of Non-Leukemic Cells and the Microenvironment in CLL Development
Chairs: Silvia Deaglio and Christopher Pepper 

Molecular Aspects of Mesenchymal Stromal Cell – CLL Cell Interactions:
New Targets Beyond B-cell Receptor Signaling Inhibition
Ingo Ringshausen
Presentation
Not Available
From Monocytes to Nurse-Like Cells:
Myeloid Cells Matter in CLL
Martina Seiffert
 view_pres-01
Effects of ibrutinib on macrophage-polarization and on the immune-response against Mycobacterium tuberculosis
Mercedes Borge
view_pres-01
Progression on ibrutinib in patients with somatic mutations in the
BCR and NF-kB pathways
Claire Sun
view_pres-01
*CLL Mutations in the Earliest Cells of the Hematopoietic Lineage: Documentation and Need for Caution
Sonia Marsilio
 view_pres-01
*IL-4R – IL-4 axis Disruption by Ibrutinib Therapy Contributes
to the Greater Vulnerability of U-CLL Clones to Loss of Microenvironmental Inputs
Shih-Shih Chen
 view_pres-01
Binet/Rai Medal Presentation
Jacques-Louis Binet and Kanti R. Rai
view_pres-01

*Selected Abstract

Please contact us at iwcll2017@bioascend.com for more information.